Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model
出版年份 2017 全文链接
标题
Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model
作者
关键词
-
出版物
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 39, Issue 6, Pages 1086-1094
出版商
Wiley
发表日期
2017-03-22
DOI
10.1002/hed.24704
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors
- (2015) J. R. Baird et al. CANCER RESEARCH
- Challenges and future perspectives of T cell immunotherapy in cancer
- (2015) Maria Teresa P. de Aquino et al. IMMUNOLOGY LETTERS
- Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model
- (2015) TAO YIN et al. Molecular Medicine Reports
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
- (2015) Olivier Demaria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
- (2015) Juan Fu et al. Science Translational Medicine
- Synthetic biology in cell-based cancer immunotherapy
- (2015) Deboki Chakravarti et al. TRENDS IN BIOTECHNOLOGY
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Harnessing the Microbiome to Enhance Cancer Immunotherapy
- (2015) Michelle H. Nelson et al. Journal of Immunology Research
- Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma
- (2014) Raymond Yung et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
- (2014) D. Chandra et al. Cancer Immunology Research
- STING-Dependent Recognition of Cyclic di-AMP Mediates Type I Interferon Responses during Chlamydia trachomatis Infection
- (2013) J. R. Barker et al. mBio
- Modified STING-activating cyclic dinucleotide derivatives significantly enhance the anti-tumor activity of therapeutic vaccines
- (2013) Meredith Leong et al. Journal for ImmunoTherapy of Cancer
- STING and the innate immune response to nucleic acids in the cytosol
- (2012) Dara L Burdette et al. NATURE IMMUNOLOGY
- Optimization of an orthotopic murine model of head and neck squamous cell carcinoma in fully immunocompetent mice – Role of toll-like-receptor 4 expressed on host cells
- (2011) Anne-Kristin Vahle et al. CANCER LETTERS
- Cyclic di-nucleotides: new era for small molecules as adjuvants
- (2011) Rimma Libanova et al. Microbial Biotechnology
- Control of Cervicovaginal HPV-16 E7-Expressing Tumors by the Combination of Therapeutic HPV Vaccination and Vascular Disrupting Agents
- (2010) Qi Zeng et al. HUMAN GENE THERAPY
- TheN-Ethyl-N-Nitrosourea-InducedGoldenticketMouse Mutant Reveals an Essential Function ofStingin theIn VivoInterferon Response toListeria monocytogenesand Cyclic Dinucleotides
- (2010) John-Demian Sauer et al. INFECTION AND IMMUNITY
- Patterns of Pathogenesis: Discrimination of Pathogenic and Nonpathogenic Microbes by the Innate Immune System
- (2009) Russell E. Vance et al. Cell Host & Microbe
- Recent Advances in Cancer Therapy: An Overview
- (2009) A. Urruticoechea et al. CURRENT PHARMACEUTICAL DESIGN
- A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP
- (2009) Sarah M. McWhirter et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now